The APCCC in Basel, Switzerland: Day 1

So in this series of reports on what happened at the 3rd Advanced Prostate Cancer Consensus Conference (APCCC) in Basel, Switzerland, we will not be trying to get into detail about exactly what data got presented each day. … READ MORE …

FDA approves new technique for “ablation of prostate tissue”

According to a media release issued by a Canadian company called Profound Medical on August 16, the US Food and Drug Administration (FDA) has approved the use of a system called TULSA-PRO for the “ablation of prostate tissue”. There appears to be no relevant information on the FDA web site — as yet. … READ MORE …

Are “manograms” a viable option in prostate cancer screening and risk assessment?

For several years, Dr. Jelle Barentz in the Netherlands has been a prominent advocate for the idea that we might be able to use imaging methodologies (prostate “manograms”, like breast mammograms for women) to screen for risk of prostate cancer — either along with or instead of PSA testing. … READ MORE …

Precision medicine and primary Gleason pattern 5 prostate cancer

Patients who are initially diagnosed with primary Gleason pattern 5 localized prostate cancer (i.e., having Gleason scores of 5 + 5 = 10 and 5 + 4 = 9) are well understood to have very high-risk disease. … READ MORE …

If you are or ever were a fighter pilot …

Apparently the US Air Force (USAF) has become concerned that being a fighter pilot may increase risk for a diagnosis of prostate cancer. For those who are interested, here’s a link to the relevant article on the McClatchy news service. … READ MORE …

The continuing importance of the digital rectal exam

Many men dislike digital rectal examinations (DREs) — for all sorts of reasons. However, a new study has again pointed out the value of the DRE in helping to establish clinical risk and the potential aggressiveness of a specific prostate cancer diagnosis in each individual patient. … READ MORE …

Geographic risk for advanced and metastatic prostate cancer

New research data on the epidemiology of advanced prostate cancer here in the US has confirmed something that has long been understood (albeit not previously as well documented). … READ MORE …